Temple syndrome in a patient with variably methylated CpGs at the primary MEG3/DLK1:IG-DMR and severely hypomethylated CpGs at the secondary MEG3:TSS-DMR.


Journal

Clinical epigenetics
ISSN: 1868-7083
Titre abrégé: Clin Epigenetics
Pays: Germany
ID NLM: 101516977

Informations de publication

Date de publication:
07 03 2019
Historique:
received: 27 12 2018
accepted: 28 02 2019
entrez: 9 3 2019
pubmed: 9 3 2019
medline: 22 1 2020
Statut: epublish

Résumé

The human chromosome 14q32.2 imprinted region harbors the primary MEG3/DLK1:IG-differentially methylated region (DMR) and secondary MEG3:TSS-DMR. The MEG3:TSS-DMR can remain unmethylated only in the presence of unmethylated MEG3/DLK1:IG-DMR in somatic tissues, but not in the placenta, because of a hierarchical regulation of the methylation pattern between the two DMRs. We performed molecular studies in a 4-year-old Japanese girl with Temple syndrome (TS14). Pyrosequencing analysis showed extremely low methylation levels of five CpGs at the MEG3:TSS-DMR and grossly normal methylation levels of four CpGs at the MEG3/DLK1:IG-DMR in leukocytes. HumanMethylation450 BeadChip confirmed marked hypomethylation of the MEG3:TSS-DMR and revealed multilocus imprinting disturbance (MLID) including mild hypomethylation of the H19/IGF2:IG-DMR and mild hypermethylation of the GNAS A/B:TSS-DMR in leukocytes. Bisulfite sequencing showed markedly hypomethylated CpGs at the MEG3:TSS-DMR and irregularly and non-differentially methylated CpGs at the MEG3/DLK1:IG-DMR in leukocytes and apparently normal methylation patterns of the two DMRs in the placenta. Maternal uniparental disomy 14 and a deletion involving this imprinted region were excluded. Such a methylation pattern of the MEG3/DLK1:IG-DMR has not been reported in patients with TS14. It may be possible that a certain degree of irregular hypomethylation at the MEG3/DLK1:IG-DMR has prevented methylation of the MEG3:TSS-DMR in somatic tissues and that a hypermethylation type MLID has occurred at the MEG3/DLK1:IG-DMR to yield the apparently normal methylation pattern in the placenta.

Sections du résumé

BACKGROUND
The human chromosome 14q32.2 imprinted region harbors the primary MEG3/DLK1:IG-differentially methylated region (DMR) and secondary MEG3:TSS-DMR. The MEG3:TSS-DMR can remain unmethylated only in the presence of unmethylated MEG3/DLK1:IG-DMR in somatic tissues, but not in the placenta, because of a hierarchical regulation of the methylation pattern between the two DMRs.
METHODS
We performed molecular studies in a 4-year-old Japanese girl with Temple syndrome (TS14).
RESULTS
Pyrosequencing analysis showed extremely low methylation levels of five CpGs at the MEG3:TSS-DMR and grossly normal methylation levels of four CpGs at the MEG3/DLK1:IG-DMR in leukocytes. HumanMethylation450 BeadChip confirmed marked hypomethylation of the MEG3:TSS-DMR and revealed multilocus imprinting disturbance (MLID) including mild hypomethylation of the H19/IGF2:IG-DMR and mild hypermethylation of the GNAS A/B:TSS-DMR in leukocytes. Bisulfite sequencing showed markedly hypomethylated CpGs at the MEG3:TSS-DMR and irregularly and non-differentially methylated CpGs at the MEG3/DLK1:IG-DMR in leukocytes and apparently normal methylation patterns of the two DMRs in the placenta. Maternal uniparental disomy 14 and a deletion involving this imprinted region were excluded.
CONCLUSIONS
Such a methylation pattern of the MEG3/DLK1:IG-DMR has not been reported in patients with TS14. It may be possible that a certain degree of irregular hypomethylation at the MEG3/DLK1:IG-DMR has prevented methylation of the MEG3:TSS-DMR in somatic tissues and that a hypermethylation type MLID has occurred at the MEG3/DLK1:IG-DMR to yield the apparently normal methylation pattern in the placenta.

Identifiants

pubmed: 30846001
doi: 10.1186/s13148-019-0640-2
pii: 10.1186/s13148-019-0640-2
pmc: PMC6407230
doi:

Substances chimiques

Calcium-Binding Proteins 0
DLK1 protein, human 0
MEG3 non-coding RNA, human 0
Membrane Proteins 0
RNA, Long Noncoding 0

Types de publication

Case Reports Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

42

Références

Nature. 2012 Nov 1;491(7422):56-65
pubmed: 23128226
PLoS Genet. 2014 Dec 11;10(12):e1004868
pubmed: 25501653
Genet Med. 2017 Apr;19(4):476-482
pubmed: 27632690
Nat Rev Endocrinol. 2017 Feb;13(2):105-124
pubmed: 27585961
J Med Genet. 2018 Jul;55(7):497-504
pubmed: 29574422
J Hum Genet. 2016 Jun;61(6):547-53
pubmed: 26911352
Hum Mutat. 2013 Apr;34(4):595-602
pubmed: 23335487
PLoS Genet. 2010 Jun 17;6(6):e1000992
pubmed: 20585555
Epigenetics. 2018;13(2):117-121
pubmed: 27911167
Eur J Hum Genet. 2012 Sep;20(9):928-32
pubmed: 22353941
J Med Genet. 2011 Jan;48(1):55-63
pubmed: 20972248
Nat Genet. 2008 Feb;40(2):237-42
pubmed: 18176563
Genet Med. 2014 Dec;16(12):903-12
pubmed: 24810686
Pediatrics. 2001 Nov;108(5):E92
pubmed: 11694676
J Pediatr. 2009 Dec;155(6):900-903.e1
pubmed: 19800077
Dev Cell. 2014 Oct 13;31(1):19-33
pubmed: 25263792
J Hum Genet. 2016 Feb;61(2):87-94
pubmed: 26377239
Eur J Hum Genet. 2015 Aug;23(8):1062-7
pubmed: 25351781
J Clin Endocrinol Metab. 2018 Jun 1;103(6):2083-2088
pubmed: 29878129
Genet Med. 2017 Dec;19(12):1356-1366
pubmed: 28640239
Epigenomics. 2016 Jun;8(6):801-16
pubmed: 27323310
J Med Genet. 2014 Aug;51(8):495-501
pubmed: 24891339

Auteurs

Masayo Kagami (M)

Department of Molecular Endocrinology, National Research Institute for Child Health and Development, 2-10-1 Okura, Setagaya-ku, Tokyo, 157-8535, Japan. kagami-ms@ncchd.go.jp.

Atsuhiro Yanagisawa (A)

Department of Pediatrics, Yaizu City Hospital, 1000 Doubara, Yaizu, Shizuoka, 425-8505, Japan.
Department of Pediatrics, JR Tokyo General Hospital, 2-1-3 Yoyogi, Shibuya-ku, Tokyo, 151-8528, Japan.

Miyuki Ota (M)

Department of Pediatrics, Yaizu City Hospital, 1000 Doubara, Yaizu, Shizuoka, 425-8505, Japan.

Kentaro Matsuoka (K)

Department of Pathology, Dokkyo Medical University, Saitama Medical Center, 2-1-50 Minami-Koshigaya, Koshigaya, Saitama, 343-8555, Japan.

Akie Nakamura (A)

Department of Molecular Endocrinology, National Research Institute for Child Health and Development, 2-10-1 Okura, Setagaya-ku, Tokyo, 157-8535, Japan.
Department of Pediatrics, Hokkaido University Graduate School of Medicine, Kita 15, Nishi 7, Kita-ku, Sapporo, 060-8638, Japan.

Keiko Matsubara (K)

Department of Molecular Endocrinology, National Research Institute for Child Health and Development, 2-10-1 Okura, Setagaya-ku, Tokyo, 157-8535, Japan.

Kazuhiko Nakabayashi (K)

Department of Maternal-Fetal Biology, National Research Institute for Child Health and Development, 2-10-1 Okura, Setagaya-ku, Tokyo, 157-8535, Japan.

Shuji Takada (S)

Department of Systems BioMedicine, National Research Institute for Child Health and Development, 2-10-1 Okura, Setagaya-ku, Tokyo, 157-8535, Japan.

Maki Fukami (M)

Department of Molecular Endocrinology, National Research Institute for Child Health and Development, 2-10-1 Okura, Setagaya-ku, Tokyo, 157-8535, Japan.

Tsutomu Ogata (T)

Department of Molecular Endocrinology, National Research Institute for Child Health and Development, 2-10-1 Okura, Setagaya-ku, Tokyo, 157-8535, Japan. tomogata@hama-med.ac.jp.
Department of Pediatrics, Hamamatsu University School of Medicine, 1-20-1 Handayama, Higashi-ku, Hamamatsu, Shizuoka, 431-3192, Japan. tomogata@hama-med.ac.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH